• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 07, 2022 at 12:02: AM
via Bristol Myers Squibb laid out some big plans over the last couple of years for its Celgene-acquired anemia drug Reblozyl, forecasting a $4 billion-plus peak sales estimate on the back of several potential label expansions.

article source
 




Top Bottom
Back
Quote